285 related articles for article (PubMed ID: 23539885)
1. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
[TBL] [Abstract][Full Text] [Related]
2. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
[TBL] [Abstract][Full Text] [Related]
4. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.
Devroey P; Pellicer A; Nyboe Andersen A; Arce JC;
Fertil Steril; 2012 Mar; 97(3):561-71. PubMed ID: 22244781
[TBL] [Abstract][Full Text] [Related]
5. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation.
Doody KJ; Schnell VL; Foulk RA; Miller CE; Kolb BA; Blake EJ; Yankov VI
Fertil Steril; 2009 Apr; 91(4):1012-7. PubMed ID: 18371963
[TBL] [Abstract][Full Text] [Related]
6. Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support.
Beltsos AN; Sanchez MD; Doody KJ; Bush MR; Domar AD; Collins MG
Reprod Health; 2014 Nov; 11():78. PubMed ID: 25385669
[TBL] [Abstract][Full Text] [Related]
7. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
8. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
[TBL] [Abstract][Full Text] [Related]
9. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.
Bosch E; Vidal C; Labarta E; Simon C; Remohi J; Pellicer A
Hum Reprod; 2008 Oct; 23(10):2346-51. PubMed ID: 18583332
[TBL] [Abstract][Full Text] [Related]
10. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
[TBL] [Abstract][Full Text] [Related]
11. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
[TBL] [Abstract][Full Text] [Related]
12. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
Ye H; Huang G; Pei L; Zeng P; Luo X
Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
[TBL] [Abstract][Full Text] [Related]
13. [Comparative randomized controlled study between human follicle- stimulating hormone (FSH-HP) and human menopausal gonadotropins (hMG) in in vitro fertilization].
Mayenga JM; Belaisch-Allart J; Chouraqui A; Tesquier L; Serkine AM; Cohen J; Plachot M; Mandelbaum J
Contracept Fertil Sex; 1997 May; 25(5):371-4. PubMed ID: 9273107
[TBL] [Abstract][Full Text] [Related]
14. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer.
Mitwally MF; Diamond MP; Abuzeid M
Fertil Steril; 2010 Feb; 93(2):554-69. PubMed ID: 19362305
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
Andersen AN; Devroey P; Arce JC
Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
[TBL] [Abstract][Full Text] [Related]
16. Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol.
Shavit T; Shalom-Paz E; Samara N; Aslih N; Michaeli M; Ellenbogen A
Gynecol Endocrinol; 2016 Aug; 32(8):629-633. PubMed ID: 26939574
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
[TBL] [Abstract][Full Text] [Related]
18. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
[TBL] [Abstract][Full Text] [Related]
19. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
[TBL] [Abstract][Full Text] [Related]
20. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]